Long-Term Octreotide Therapy in Growth Hormone-Secreting Pituitary Adenomas:Evaluation with Serial MR
AJNR 18:765-772, Lundin,P.,et al, 1997
Intracranial Aneurysm Enlargement on Serial Magnetic Resonance Angiography: Frequency and Risk Factors
Stroke 40:406-411, Burns,J.D.,et al, 2009
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Case-Based Review of Cerebral Venous Infarcts with Perfusion Imaging and Comparision to Arterial Ischemic Stroke
Front Radiol 1:687045, Li, A.Y.,et al, 2021
Infliximab for the Treatment of CNS Sarcoidosis
Neurol 89:2092-2100, Gelfand, J.M.,et al, 2017
Clinicopathologic Conference, Neurosarcoidosis
NEJM 374:1966-1975, Case 15-2016, 2016
Radiation Necrosis in Pediatric Patients with Brain Tumors Treated with Proton Radiotherapy
AJNR 36:1572-1578, Kralik, S.F.,et al, 2015
PML-IRIS in a patient treated with Brentuximab
Neurol 79:2075-2077, Geldern, G.,et al, 2012
Posterior Reversible Encephalopathy Syndrome: Long-Term Follow-Up
JNNP 81:773-777, Roth,C. &Ferbert,A., 2010
Hemorrhagic Manifestations of Reversible Cerebral Vasoconstriction Syndrome: Frequency, Features, and Risk Factors
Stroke 41:2505-2511, 2455, Ducros,A.,et al, 2010
MRI Outcomes in a Placebo-Controlled Trial of Natalizumab in Relapsing MS
Neurol 68:1390-1401, Miller,D.H.,et al, 2007
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
Early Ischemic Lesion Recurrence Within a Week After Acute Ischemic Stroke
Ann Neurol 54:66-74, Kang,D.,et al, 2003
Benefit of Interferon B-1a on MSFC Progression in Secondary Progressive MS
Neurol 59:679-687, Cohen,J.A.,et al, 2002
Copaxone's Effect on MRI-Monitored Disease in Relapsing MS is Reproducible and Sustained
Neurol 59:1284-1286, Wolinsky,J.S.,et al, 2002
Assessing the Risk of Early Multiple Sclerosis in Patients with Clinically Isolated Syndromes: the Role of a Follow Up MRI
JNNP 70:390-393, Brex,P.A.,et al, 2001
European/Canadian Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Glatiramer Acetate on Magnetic Resonance Imaging-Measured Disease Activity and Burden in Patients wi
Ann Neurol 49:290-297, Comi,G.,et al, 2001
Spontaneous Dissection of the Carotid and Vertebral Arteries
NEJM 344:898-906, Schievink,W.I., 2001
Effect of Early Interferon Treatment on Conversion to Definite Multiple Sclerosis: A Randomised Study
Lancet 357:1576-1582,1547, Comi,G.,et al, 2001
Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1505-1513, Li,D.K.B.,et al, 2001
The Effect of IFNB-1b on the Evolution of Enhancing Lesions in Secondary Progressive MS
Neurol 57:2185-2190, Brex,P.A.,et al, 2001
Magnetic Resonance Imaging of Cerebral Microbleeds
Current Opinion in Neurology 13:69-73, Roob,G.&Fazekas,F., 2000
Herpes Varicella Zoster Encephalitis in Immunocompromised Patients
Neurol 52:193-195, Weaver,S.,et al, 1999
Magnetic Resonance Imaging Results of the PRISMS Trial:A Randomized, Double-Blind, Placebo-Controlled Study of Interferon-B1a in Relapsing-Remitting Multiple Scleroosis
Ann Neurol 46:197-206, Li,D.K.B.,et al, 1999
Evidence of Interferon B-1a Dose Response In Relapsing-Remitting MS, The OWIMS Study
Neurol 53:679-686, The Once Weekly Interferon for MS Study Group (OWI, 1999
Interferon-B-1a in Relapsing-Remitting Multiple Sclerosis:Effect on Hypointense Lesion Volume on T1 Weighted Images
JNNP 67:579-584, Gasperini,C.,et al, 1999
Effect of Steroids on Gd-Enhancing Lesions Before & During Beta Interferon 1a Trtm in Relapsing Remitting MS
Neurol 50:403-406, Gasperini,C.,et al, 1998
Regress of HIV Enceph & Basal Ganglia Signal Intensity Abnor MRI in AIDS after Protease Inhibitor
Neuroradiology 206:491-498, Filippi,C.G.,et al, 1998
Magnetic Resonance Imaging Lesion Analysis in Neurofibromatosis Type 1
Arch Neurol 55:500-505, DiMario,F.J.&Ramsby,G., 1998
Effects of Copolymer-1 on Serial Gadolinium-Enhanced MRI in Relapsing Remitting Multiple Sclerosis
Neurol 50:1127-1133, Mancardi,G.L.,et al, 1998
Mass Effect in Progressive Multifocal Leukoencephalopathy
Arch Neurol 55:1148-1149, Finelli,P.F., 1998
Cerebral Amyloid Angiopathy:Propsects for Clinical Diagnosis and Treatment
Neurol 52:690-694, Greenberg,S.M., 1998
Randomised Double-Blind Placebo-Controlled Study of Interferon B-1a in Relapsing/Remitting Multiple Sclerosis
Lancet 352:1498-1504,1486, PRISMS, 1998
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Progressive Multifocal Leukoencephalopathy in AIDS:Initial and Follow-up CT and MRI
Neuroradiology 39:611-618, Thurnher,M.M.,et al, 1997
Evolution of High-Intensity Basal Ganglia Lesions on T1-Weighted MR in Neurofibramotisis Type 1
AJNR 17:755-760, Terada,H.A.,et al, 1996
Neutralizing Antibodies During Treatment of Multiple Sclerosis with Interferon Beta-1b
IFNB MS Study Group & UBC MS. MRI Analysis Group, Neurol 47:889-8946., , 1996